A detailed history of Walleye Capital LLC transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Walleye Capital LLC holds 127,588 shares of BEAM stock, worth $3.43 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
127,588
Previous 104,924 21.6%
Holding current value
$3.43 Million
Previous $2.46 Million 27.14%
% of portfolio
0.01%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$22.57 - $33.14 $511,526 - $751,084
22,664 Added 21.6%
127,588 $3.13 Million
Q2 2024

Aug 14, 2024

BUY
$21.22 - $32.66 $152,508 - $234,727
7,187 Added 7.35%
104,924 $2.46 Million
Q1 2024

May 15, 2024

BUY
$23.46 - $45.07 $2.29 Million - $4.41 Million
97,737 New
97,737 $3.23 Million
Q4 2021

Mar 03, 2022

SELL
$68.02 - $99.06 $328,468 - $478,360
-4,829 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$84.37 - $133.6 $407,422 - $645,154
4,829 New
4,829 $420,000

Others Institutions Holding BEAM

About Beam Therapeutics Inc.


  • Ticker BEAM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,354,600
  • Market Cap $1.89B
  • Description
  • Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...
More about BEAM
Track This Portfolio

Track Walleye Capital LLC Portfolio

Follow Walleye Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Walleye Capital LLC with notifications on news.